Novo Nordisk and Eli Lilly control 63.6% of all active GLP-1/obesity trials and 74.2% of total enrollment. With 47 combined Phase 3 trials, these two companies will define the market for the next 2-3 years. But cracks are appearing — oral small molecules, reduced GI side effects, and Chinese biotechs are creating new opportunities.
Executive Summary
The GLP-1 receptor agonist market has exploded from a niche diabetes treatment to the most competitive therapeutic area in pharma. With Wegovy and Ozempic generating combined revenues exceeding $30B in 2025, every major pharmaceutical company wants a piece.
We analyzed 614 active clinical trials for GLP-1 receptor agonists and obesity drugs from ClinicalTrials.gov — the most comprehensive real-time dataset available. Here's what the data reveals about the competitive landscape, market gaps, and strategic opportunities.
Table of Contents
1. Market Leaders: The Novo Nordisk vs Eli Lilly Duopoly
The GLP-1/obesity market is not a competitive landscape — it's a duopoly. Our analysis of 614 active commercial trials shows just how dominant the two leaders are:
Novo Nordisk leads with 34 active trials and 165,176 total enrollment — nearly 4x more than any other company. Eli Lilly follows with 29 trials and 46,000 enrollment. Together, they account for 63.6% of all active commercial trials and control 74.2% of total patient enrollment.
If you combine only their Phase 3 trials, you get 31 Phase 3 trials between two companies. That's more Phase 3 activity than the entire rest of the industry combined.
Novo Nordisk: The Incumbent King
Novo Nordisk's dominance is structural. With Wegovy and Ozempic already generating blockbuster revenues, the company has the resources, manufacturing capacity, and clinical infrastructure to run the largest pipeline in history. Their 13 Phase 3 trials span:
- Next-generation GLP-1 molecules (NNC0487-0111, NNC0497-0040, UBT251) with improved efficacy
- New indications — NASH, CKD, cardiovascular disease, Alzheimer's
- Pediatric and adolescent obesity trials
- Head-to-head superiority trials against competitors
The threat to Novo Nordisk isn't another GLP-1 — it's a superior mechanism that makes semaglutide obsolete. That's why their pipeline extends far beyond simple GLP-1 agonism.
Eli Lilly: The Aggressive Challenger
Eli Lilly's strategy is fundamentally different. While Novo protects its semaglutide franchise, Lilly is betting on mechanism innovation. Their 18 Phase 3 trials (more than any competitor) focus on:
- Tirzepatide — dual GLP-1/GIP agonist, already approved for diabetes (Mounjaro) and obesity (Zepbound)
- Retatrutide — triple agonist (GLP-1/GIP/glucagon), Phase 3 data shows up to 24% body weight reduction
- Eloralintide — long-acting amylin analog, complementary mechanism
Lilly's Phase 3 count exceeds Novo's (18 vs 13), signaling aggressive intent to capture the next-generation market. If retatrutide demonstrates superior efficacy and tolerability, Lilly could leapfrog Novo within 3-4 years.
2. Rising Challengers: Big Pharma Enters the Fray
The duopoly hasn't scared away big pharma — it's attracted them. Amgen, Roche, AstraZeneca, Regeneron, and Boehringer Ingelheim all have active GLP-1 programs, though most are still in earlier phases.
Regeneron: The Antibody Approach
Regeneron stands out by taking a fundamentally different approach — antibody-based therapeutics instead of peptides or small molecules. With 5 active trials (all Phase 1/2), their REGN20934 program targets obesity through novel pathways. Regeneron's expertise in antibody engineering ( Provenge, Eylea ) could give them a manufacturing and IP advantage if their GLP-1 program advances.
Boehringer Ingelheim: The Dark Horse
Boehringer has only 3 active trials, but they're the most ambitious by enrollment — 230,094 total participants across just 3 studies (76,698 per trial on average). Their BI 456906 dual agonist and Survodutide program suggests serious commitment. Boehringer's strength is metabolic disease — they already have a significant diabetes portfolio and deep expertise in combination therapies.
AstraZeneca and Amgen: Playing Catch-Up
AstraZeneca's AZD1043 and Amgen's maridebart cafraglutide represent traditional big pharma entries — well-funded, methodical, but late to the party. Amgen has the advantage of being first with an antibody-based GLP-1 approach, but both companies trail by 2-3 years in development timeline.
3. Emerging Players: Small Molecules and Chinese Biotechs
The most interesting competitive dynamics are happening outside the traditional big pharma circle. Two categories of new entrants are disrupting the landscape:
Oral Small-Molecule GLP-1s
Today's GLP-1 drugs are all injectable. The first company to bring an effective oral GLP-1 to market would unlock a massive addressable population — patients who refuse injections represent an estimated 40-60% of the eligible obesity population.
- Viking Therapeutics (VK2735) — 2 Phase 3 trials, 5,600 enrollment. Oral small molecule, 100% Phase 3 pipeline. This is the most advanced oral GLP-1 program.
- Hudson Biotech (MOTS-c) — Unique mitochondrial-targeting approach, Phase 3 underway. Different mechanism entirely — not GLP-1 but achieves similar metabolic benefits.
- Gasherbrum Bio (Aleniglipron) — Small molecule GLP-1 receptor agonist, Phase 3. Subsidiary of Structure Therapeutics.
Chinese Biotechs: Cost Disruptors
China has emerged as the second GLP-1 battleground after the US. Chinese biotechs are developing GLP-1 alternatives for domestic use and potentially export to emerging markets:
- Innovent Biologics (IBI362) — Dual agonist similar to Lilly's tirzepatide, Phase 3 underway. Strong Chinese market position, could expand globally.
- Gan & Lee Pharmaceuticals (GZR series) — Multiple GLP-1 candidates, Phase 3 in progress. Cost-competitive manufacturing is their core advantage.
The threat from Chinese biotechs isn't immediate in Western markets, but in 5-7 years, cost-competitive biosimilars and next-gen alternatives could pressure pricing globally — similar to what happened with insulin.
4. Market Gaps & Untapped Opportunities
Despite the crowded field, significant market gaps remain. These represent the highest-value opportunities for new entrants:
Gap #1: Oral GLP-1 Agonists (High Severity)
No oral GLP-1 has reached Phase 3 yet. Viking's VK2735 is closest but still unproven at scale. The first company to demonstrate oral bioavailability equivalent to injectable efficacy captures the "needle-phobic" market — potentially 40-60% of eligible patients.
Gap #2: Reduced GI Side Effects (High Severity)
Nausea, vomiting, and diarrhea are the #1 reason for discontinuation in GLP-1 therapy. Current discontinuation rates range from 25-40% within the first 3 months. A GLP-1 with comparable efficacy but significantly reduced GI side effects would be a paradigm shift — potentially a $10-15B standalone opportunity.
Gap #3: Pure Obesity (No Diabetes Indication)
Most GLP-1 drugs are developed for diabetes first, then tested for obesity. A molecule specifically optimized for obesity (without glycemic effects) could have cleaner safety profiles and simpler clinical development — potentially 12-18 months faster to market.
Gap #4: Long-Acting Formulations (Medium Severity)
Weekly dosing is the current standard. Monthly or longer dosing intervals would dramatically improve adherence. This is especially valuable for patients who struggle with weekly injection schedules.
Gap #5: Cost-Effective Manufacturing (Medium Severity)
Current GLP-1 manufacturing requires complex peptide synthesis, contributing to high costs. A biosimilar or alternative manufacturing process could enable 50-70% cost reduction — transformative for emerging markets and payers globally.
5. Methodology
This analysis was conducted using TrialScope, a Chrome extension for clinical trial intelligence. Data was collected from ClinicalTrials.gov API v2 using the following search queries:
- Condition: obesity (14,592 results), overweight (13,753 results)
- Intervention: semaglutide (712), tirzepatide (252), liraglutide (512), exenatide (376), dulaglutide (138), retatrutide (33), GLP-1 receptor agonist (432)
After deduplication and relevance filtering, 2,021 GLP-1/obesity-related trials were identified. Of these, 614 are actively recruiting or ongoing. Commercial sponsors were filtered from academic/government institutions using keyword matching and a known-pharma allowlist.
AI-powered competitive analysis was performed using StepFun's step-3.7-flash model with structured function calling to ensure reliable, data-grounded insights.
6. Strategic Implications for BD Teams
What does this mean for pharma BD professionals, biotech founders, and investors?
For Big Pharma BD
The duopoly creates a clear strategic imperative: acquire or partner. The easiest way to compete with Novo Nordisk and Eli Lilly isn't to outspend them on Phase 3 — it's to acquire promising Phase 1/2 assets from emerging players (Viking, Gasherbrum, Innovent) before they mature. M&A activity in this space will accelerate.
For Biotech Founders
The market gaps are well-defined, but execution risk is high. The most fundable opportunities are:
- Oral GLP-1 with differentiated PK — first-to-market advantage is massive
- GI side effect reduction platform — formulation technology or prodrug approach
- China-first strategy — develop for the Chinese market, then expand
For Investors
The GLP-1 market is not a winner-take-all — it's a winner-take-most scenario. The top 2 companies will capture 60-70% of the market. Investment returns will concentrate in:
- Companies with Phase 3 oral GLP-1 programs (Viking at $5.6B market cap as of mid-2026)
- Next-gen mechanism innovators (retatrutide-class molecules, dual/triple agonists)
- Adjacent opportunities (CKD, NASH, Alzheimer's — indications that leverage GLP-1 biology)
Automate your competitive intelligence.
TrialScope pulls CT.gov data, runs AI analysis, and generates reports like this — in minutes, not days.